PSA Cut-Point Indicates When to Start Salvage Radiotherapy in Prostate Cancer
March 24th 2023An expert from Dana-Farber Cancer Institute indicates that patients with prostate cancer who have 1 risk factor should undergo salvage radiotherapy following radical prostatectomy before their prostate-specific antigen level rises above 0.25 ng/ml.
Peter Humphrey, MD, PhD, Discusses Histology and Clinical Trial Enrollment in RCC
April 25th 2022At the 15th Annual Interdisciplinary Prostate Cancer Congress® and Other Genitourinary Malignancies, Peter Humphrey, MD, PhD, spoke about how enrollment for specific trials in renal cell carcinoma may incorporate a patient’s tumor histology.
Daniel P. Petrylak, MD, Reviews Ongoing Clinical Trials in Bladder Cancer
April 22nd 2022At the 15th Annual Interdisciplinary Prostate Cancer Congress® and Other Genitourinary Malignancies, Daniel P. Petrylak, MD, spoke about ongoing trials may hold promise for the treatment of patients with bladder cancer.
Peter Humphrey, MD, PhD, Talks Multidisciplinary Aspects of Oncology Research
April 7th 2022At the 15th Annual Interdisciplinary Prostate Cancer Congress® and Other Genitourinary Malignancies, Peter Humphrey, MD, PhD, spoke about how the conference catered to the multidisciplinary audience, and what he learned from that.
Immunotherapy Continues to Influence Perioperative Bladder Cancer Management
March 18th 2022At the recent 15th Annual Interdisciplinary Prostate Cancer Congress® and Other Genitourinary Malignancies, Jean Hoffman-Censits, MD, reviews advances in the use of systemic therapy to aid surgical management of bladder cancer.
Combining Surgical and Therapeutic Treatment Options in Evolving Field of RCC
March 16th 2022Gennady Bratslavsky, MD, discusses the ever-changing field of treatment options for renal cell carcinoma at the 15th Annual Interdisciplinary Prostate Cancer Congress® and Other Genitourinary Malignancies, hosted by Physicians’ Education Resource®, LLC.
As Treatment Options Abound, Clinicians Rely on Risk Stratification for Frontline RCC Management
March 15th 2022Primo Nery Lara, Jr., MD, talks treatment of metastatic renal cell carcinoma in the first-line setting at the 15th Annual Interdisciplinary Prostate Cancer Congress® and Other Genitourinary Malignancies, hosted by Physicians’ Education Resource®, LLC.
Expert Explores the Current Status of Radium-223 Use in Castration-Resistant Prostate Cancer
March 28th 2021During a presentation at the 14th Annual New York GU Interdisciplinary Prostate Cancer Congress® and Other Genitourinary Malignancies, Scott T. Tagawa, MD, reviewed important findings related to radium-223 and its use in patients with castration-resistant prostate cancer.
How To Implement Next-Generation Imaging Recommendations in Prostate Cancer Management
March 26th 2021At the New York GU 14th Annual Interdisciplinary Prostate Cancer Congress® and Other Genitourinary Malignancies, Phillip J. Koo, MD, discussed the recommendations issued for the early detection of metastatic prostate cancer using next-generation imaging.
Updated Standard Practice for Managing Patients with Non-Muscle-Invasive Bladder Cancer
March 13th 2021Leonard G. Gomella, MD, FACS, detailed updated information regarding the standard of care and overall management of patients with non-muscle invasive bladder cancer at the 2021 New York GU 14th Annual Interdisciplinary Prostate Cancer Congress®.
Management of Upper Tract Urothelial Tumors With Conservative Management, Mitomycin Gel
March 12th 2021Scott G. Hubosky, MD, of Jefferson University Hospitals, discussed methods of treating patients with upper tract urothelial carcinoma at the 2021 New York GU 14th Annual Interdisciplinary Prostate Cancer Congress®.